If we are going to argue that Mexico is the structurally correct answer, we owe you the receipts.
The five preceding pages, §2.1 on Mexico for Americans, §2.2 on the Western Hemisphere alternatives, §2.3 on Germany and Japan, §2.4 on the world map, and §2.5 on Tijuana: make a long list of factual claims about countries, regulators, and hospitals. Some of those claims sit at the heart of our argument. All of them need a public source we can point you to and a method we can defend. This page is that source list.
The rule is the same one used in §6.4: every claim about a country, regulator, or hospital must be sourced to a public document at the time of writing, or labeled "not stated" if the public material is silent. We rely on four classes of source: regulator (WHO, FDA, COFEPRIS), independent NGO (national hospital certification, Patients Beyond Borders, peer-reviewed indices), press of record, and clearly-labeled internal estimates. We do not source to private conversations, leaked documents, or competitor sales materials.
42 numbered.
Across §2.1 through §2.5. every [n] in the prior pages resolves to a row in the table below.
Public only.
Regulator listings, WHO/NGO data, peer-reviewed papers, government statistics, our own internal records when labeled as such.
Reviewed quarterly.
If a referenced source changes materially: a regulator delisting, a international hospital accreditation lapse, a new advisory tier, both the table and the source page update together.
Prefer to watch?
The receipts, on camera.
This page is a 7-minute read. The video walks the same sourcing rule: fewer claims, each tied to a public document we can point you to. Keep scrolling for the full version.
What we did, and what we deliberately didn't.
Country-level claims are easier to mis-source than clinic-level claims, because the underlying material is voluminous and the temptation is to lean on a single Wikipedia paragraph. We did not do that. The eight rules below are the same ones used for the §6 comparison work, adapted to country and regulator claims.
Four did's, four didn'ts.
For every claim about a country's regulator (COFEPRIS, FDA, EMA, PMDA, MHRA, Health Canada, Swissmedic, TGA, INVIMA, MINSA, COFEPRIS et al.), we cite the regulator's own published framework or the WHO's listing of that regulator, not a secondary summary.
Wikipedia is fine as a navigation tool. It is not fine as a primary source for a claim a patient is about to act on. Where Wikipedia surfaced a useful pointer, we followed the citation chain to the underlying document and sourced to that.
Some numbers in Section 2 are aggregations or our own modeled estimates, for example, the U.S.-fellowship share of Hospital Angeles specialists in §2.1. Those rows are labeled INTERNAL · ESTIMATE in the source column and the basis is explained inline.
Phrases like "studies have shown" or "research suggests" with no actual study cited are not used. If we cannot point to the underlying source, we either rewrite the claim more cautiously or drop it.
Counts that move (private-network hospital counts, advisory-tier assignments, registry listings) are cited against a dated snapshot. The changelog at the foot of this page records the snapshot date; live counts may have moved since.
We do not make derogatory or sweeping claims about Panama, Cayman, Germany, Japan, or any other country. We make narrowly-sourced structural claims, "regulator X uses framework Y; advisory tier Z". and let the reader draw the comparison.
If a regulator, hospital, or NGO believes we have characterized them inaccurately, [email protected] reaches our medical director and counsel directly. Material corrections post within five business days; cosmetic edits roll into the quarterly cycle.
Where a number could be rounded up or down, we rounded to the figure the public source actually publishes, not to whichever value flatters our argument. The 1.4 million U.S. patient figure is Patients Beyond Borders' own published estimate, not our reframe of it.
The combined effect is that Section 2 is shorter and more cautious than it would be if we wrote it the way a marketing team would. Some genuinely true claims about Mexico get cut because we cannot source them publicly. Some genuinely problematic facts about competing destinations are left implicit because we will not write derogatory country rows we cannot substantiate. That is the trade, fewer claims, defensible claims.
Where the 42 references actually come from.
Read the chart left-to-right: the longer the bar, the more sourced claims that article makes. §2.1 is by far the densest because it does the heaviest lifting of the section, it carries the country-level argument. Read top-to-bottom: every article is anchored by regulator and NGO sources (the two darker colors). The two source classes we hold to the highest standard, regulator and independent NGO, together account for 32 of 42 references (76%). Press and internal-estimate sources, which we treat as weaker, account for the remaining 10.
What kind of evidence backs each row.
Each row in the reference table below carries a "source class" tag. The four classes, in descending order of how directly they constitute primary evidence:
Official framework documents, registry entries, and inspection records from WHO, FDA, COFEPRIS, EMA, PMDA, Health Canada, MHRA, Swissmedic, TGA, INVIMA, MINSA, etc. Primary evidence.
Patients Beyond Borders annual reports, peer-reviewed indices, transparency-international country indices, OECD health data, corporate disclosures from major hospital networks. Strong independent evidence.
Major outlets: NYT, WSJ, BMJ, NEJM, Nature, Reuters, AP, Mexican press of record (Reforma, El País, Milenio), for facts and dates that are themselves public. Acceptable secondary evidence.
Our own records or modeled estimates, clearly labeled. Used for claims we are best-positioned to know (e.g. Celva's own travel logistics) and for ratios where we model from public inputs. Always labeled as such.
The widest tiers carry the heaviest claims.
The pyramid is intentionally top-heavy. Three-quarters of every claim Section 2 makes: about regulators, hospitals, accreditation registries, patient flow, rests on a source we did not write and do not control. The narrow base is the small set of figures we are best-positioned to estimate (our own cost modeling, our own roster review, our own travel logistics), and those rows are always labeled as such in the references table.
The rule, by claim type.
"Required" means a claim of that type cannot appear in Section 2 unless this source class backs it. "Accepted" means it's an admissible source if the higher-tier one isn't available. ", " means that source class would not be appropriate for that claim type and we would not use it even if it were available.
Every [n] in Section 2, resolved.
Read as: "claim made → from which §2 article → source class → source name." Source names are classes (e.g. "COFEPRIS framework") rather than live URLs because regulator websites restructure routinely. Where a peer-reviewed paper, registry entry, or specific report is cited, the title or registry ID is given.
The "source" column is deliberately a class or named document rather than a live URL. Regulator websites restructure routinely, national hospital certification's registry pages move, U.S. State Department advisory permalinks change. The class names refer to whatever was published at the snapshot date recorded in the changelog. If a referenced source moves or disappears, the row gets re-reviewed and the relevant Section 2 page updates accordingly.
The honest limits of a sourced country comparison.
A footnote page is a tool. It is not a guarantee that the underlying argument is fair, complete, or current. Three limits we want explicit:
Three things this page does not give you.
- It does not give you outcome comparisons across countries. We do not claim that Mexican patients do clinically better or worse than patients treated in Germany, Japan, Panama, or Cayman. Cross-country outcome data for cell therapy is not aggregated in a way that allows that comparison and we will not invent it.
- It does not catch silent regulator changes. If COFEPRIS, national hospital certification, or the State Department change their framework, registry, or advisory tier between our review cycles, the table lags reality until the next quarterly snapshot. That is unavoidable for any source-class methodology.
- It does not adjudicate disagreement. If a regulator or an NGO reads §2.1 through §2.5 and believes we have characterized them inaccurately, this page is where they write to us. The right-of-correction note in Methodology is genuine.
How these pages stay true.
Section 2 is reviewed quarterly. The current review window is recorded below. When a referenced public source changes materially: a regulator delisting, a international hospital accreditation lapse, a new advisory tier, a major change to Patients Beyond Borders' methodology, both the table and the Section 2 page update together, with the prior version archived internally.
Last reviewed: quarterly · current cycle.
Next scheduled review: within 90 days of the last review date posted above. A material change to any cited regulator, accreditor, or NGO source between reviews triggers an out-of-cycle edit; routine wording changes wait for the cycle.
What to do if you spot something: Write to [email protected] with the page, the row number, and the public source you believe contradicts our characterization. We read every one, and we reply within five business days even when we disagree.
What we will not do: remove a row simply because a referenced party prefers it removed. The standard is evidence, not preference. If the public source supports the row, the row stays. If the public source has changed, the row changes with it.
Sourced, auditable, replaceable.
Every factual claim made in §2.1 through §2.5 about Mexico, COFEPRIS, the private-hospital network, U.S. medical-tourism flow, comparator regulators, the State Department advisory map, and the international cell-therapy landscape lands on a row in the 42-reference table on this page. The standard is public sources only: regulator frameworks, independent NGO indices, peer-reviewed papers, government statistics, clearly-labeled internal estimates. We do not compare clinical outcomes across countries. We do not use private documents. We accept right-of-correction edits. The trade we are making is fewer claims for defensible claims.